abstract |
FIELD: biotechnology; medicine; pharmaceutics. n SUBSTANCE: present invention relates to biotechnology and pharmaceutics, namely to antibody conjugates for treating rheumatoid arthritis in a patient. Antibody included in these conjugates specifically binds Extra-Domain-A (ED-A) to fibronectin and is conjugated to interleukin-10. Present invention also discloses a nucleic acid encoding said conjugate, a host cell for its production, a pharmaceutical composition for treating rheumatoid arthritis in a patient, as well as a method of producing said conjugate and a method for treating rheumatoid arthritis, a method for delivering interleukin-10 to regions of rheumatoid arthritis and method diagnosis of rheumatoid arthritis in a patient with its use. n EFFECT: present invention provides successful treatment of rheumatoid arthritis by selective delivery of interleukin-10 to sites of disease localization. n 35 cl, 8 dwg, 2 tbl, 1 ex |